The study is assessing the safety, tolerability, and biological activity of LD IL-2 in mild-to-moderate Alzheimer’s patients. Credit: fizkes / Shutterstock.

Coya Therapeutics has announced the conclusion of a Phase II clinical trial investigating low-dose interleukin-2 (LD IL-2) for the treatment of mild-to-moderate Alzheimer’s disease (AD).

Supported by the Gates Foundation and the Alzheimer’s Association, the randomised, double-blind, placebo-controlled controlled study is being conducted at Houston Methodist Hospital in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study is aimed at assessing the safety, tolerability, and biological activity of LD IL-2 in mild-to-moderate AD patients.

It will also assess the effects of LD IL-2 on blood and cerebrospinal fluid biomarkers, neuroimaging data, and changes in cognitive function.

The study involved 38 AD patients who were given either LD IL-2 or a placebo over 21 weeks, followed by a nine-week follow-up.

Topline results from the trial are expected to be reported in the third quarter of this year.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Previous findings from an open-label, proof-of-concept study indicated that LD IL-2 treatment significantly expanded the regulatory T cell (Treg) population and function in eight AD patients.

The mean (SD) percentage of Tregs rose to 8.68 at the end of treatment from 4.55 at baseline.

Additionally, the same study showed a significant improvement in Mini-Mental State Examination scores during the treatment phase.

The LD IL-2 treatment was found to be well-tolerated, with the most common adverse events being mild injection-site reactions and leukopenia.

No serious adverse events or patient discontinuations were reported in the study.

Coya Therapeutics president and CMO Fred Grossman said: “This is an important study that will help advance our expanding pipeline in dementia.

“We look forward to unblinding the data from this controlled study in Alzheimer’s disease and releasing the top-line results this summer.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact